|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-5-15
|
|
pubmed:abstractText |
Randomized trial LNH93-3 was conducted on patients who had poor-prognosis aggressive lymphoma and were younger than 60 years with two to three factors of the age-adjusted International Prognostic Index to evaluate the benefit of early high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:CoiffierBertrandB,
pubmed-author:FilletGeorgesG,
pubmed-author:GabarreJeanJ,
pubmed-author:GisselbrechtChristianC,
pubmed-author:Groupe d'Etude des Lymphomes de l'Adulte,
pubmed-author:GuilminFrancoiseF,
pubmed-author:HermineOlivierO,
pubmed-author:LederlinPierreP,
pubmed-author:LepageEricE,
pubmed-author:MolinaThierryT,
pubmed-author:QuesnelBrunoB,
pubmed-author:ReyesFélixF,
pubmed-author:TillyHervéH
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2472-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12011124-Adolescent,
pubmed-meshheading:12011124-Adult,
pubmed-meshheading:12011124-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12011124-Bleomycin,
pubmed-meshheading:12011124-Blood Cells,
pubmed-meshheading:12011124-Cyclophosphamide,
pubmed-meshheading:12011124-Doxorubicin,
pubmed-meshheading:12011124-Female,
pubmed-meshheading:12011124-Follow-Up Studies,
pubmed-meshheading:12011124-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12011124-Humans,
pubmed-meshheading:12011124-Lymphoma,
pubmed-meshheading:12011124-Male,
pubmed-meshheading:12011124-Middle Aged,
pubmed-meshheading:12011124-Neoplasm Staging,
pubmed-meshheading:12011124-Prednisone,
pubmed-meshheading:12011124-Prognosis,
pubmed-meshheading:12011124-Remission Induction,
pubmed-meshheading:12011124-Survival Rate,
pubmed-meshheading:12011124-Transplantation, Autologous,
pubmed-meshheading:12011124-Treatment Outcome,
pubmed-meshheading:12011124-Vindesine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
|
|
pubmed:affiliation |
Institut d'Hématologie, GELA Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris cedex 10, France. christian.gisselbrecht@sls.ap-hop-paris.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
